EP1776084A1 - Compositions cosmetiques pour traiter une peau stressee contenant de la taurine et des alcools gras a chaine longue - Google Patents

Compositions cosmetiques pour traiter une peau stressee contenant de la taurine et des alcools gras a chaine longue

Info

Publication number
EP1776084A1
EP1776084A1 EP05770481A EP05770481A EP1776084A1 EP 1776084 A1 EP1776084 A1 EP 1776084A1 EP 05770481 A EP05770481 A EP 05770481A EP 05770481 A EP05770481 A EP 05770481A EP 1776084 A1 EP1776084 A1 EP 1776084A1
Authority
EP
European Patent Office
Prior art keywords
skin
skin treatment
cosmetic
composition according
cosmetic skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05770481A
Other languages
German (de)
English (en)
Inventor
Thomas Döring
Armin Wadle
Marianne Waldmann-Laue
Bernd Anderheggen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henkel AG and Co KGaA
Original Assignee
Henkel AG and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE200410039550 external-priority patent/DE102004039550A1/de
Priority claimed from DE102005022626A external-priority patent/DE102005022626A1/de
Application filed by Henkel AG and Co KGaA filed Critical Henkel AG and Co KGaA
Publication of EP1776084A1 publication Critical patent/EP1776084A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/062—Oil-in-water emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/342—Alcohols having more than seven atoms in an unbroken chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/001—Preparations for care of the lips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the skin is the largest organ in humans. Among its many functions (for example, for heat regulation and as a sensory organ) is the barrier function, the one that prevents the drying of the skin (and thus ultimately the entire organism), probably the most important. At the same time, the skin acts as a protective device against the penetration and absorption of substances coming from outside. This barrier function is caused by the epidermis, which, as the outermost layer, forms the actual protective cover against the environment. At about one-tenth of the total thickness, it is also the thinnest layer of the skin.
  • the epidermis is a stratified tissue, in which the outer layer, the stratum corneum, is the part that is important for the barrier function. It is worn out in contact with the environment and is therefore in a constant renewal process, whereby outwardly continuously fine dandruff is released and from the inside keratinized cell and lipid material is produced according to.
  • Elias Skin Model PM Elias, Structure and Function of the Stratum Corneum Permeability Barrier, Drug Dev. Res. 13, 1988, 97-105
  • the horny layer as a two-component system, similar to a brick Stone Wall (Brick Mortar Model).
  • the horny cells correspond to the bricks
  • the complex lipid membrane in the intercellular spaces corresponds to the mortar.
  • This system is essentially a physical barrier against hydrophilic substances, but due to its narrow and multi-layered structure, it is also difficult to pass by lipophilic substances.
  • the special structure of the horny layer protects the skin and stabilizes its own flexibility by binding a defined amount of water.
  • the lipids of the Homtik consist essentially of ceramides, free fatty acids, cholesterol and cholesterol sulfate and are distributed over the entire Hom harsh.
  • the composition of these lipids is crucial for the intact functioning of the epidermal barrier and thus for the impermeability of the skin.
  • water-soluble substances are washed off or washed out, such as.
  • skin fats are to a certain extent dissolved and washed out by the skin's own surfactants. This causes after initial swelling a subsequent dehydration of the skin, which can be significantly enhanced by detergent additives.
  • Dry skin has a lack of barrier lipids (ceramides, cholesterol and free fatty acids) in the homtik.
  • barrier lipids ceramides, cholesterol and free fatty acids
  • the reduced integrity and repair performance of the skin barrier results in increased transepidermal water loss.
  • the skin becomes rough, dry, flaky and prone to tense as well as itching.
  • intercellular lipid mixtures such as ceramides or ceramide analogues, which are to be used by the skin to rebuild the natural barrier, are increasingly being added to the topical preparations.
  • these lipids are usually very expensive raw materials which are also difficult to formulate due to their high melting point.
  • their effect is limited because the topically applied lipids penetrate only to a small extent in the barrier-relevant lipid membranes in the middle stratum corneum and are integrated only to a small extent in these structures. Accordingly, the prior art lacks preparations which positively influence the barrier function and the hydration of the horny layer and strengthen or even restore the physicochemical properties of the horny layer and in particular the lamellae of intercellular lipids.
  • TEWL transepidermal water loss
  • taurine significantly reduced TEWL.
  • taurine on skin models significantly stimulated the synthesis of all three classes of barrier lipids, ceramides, cholesterols, and fatty acids.
  • IL-1 alpha Epidermal interleukin-1 alpha
  • SDS sodium dodecyl sulfate
  • IL-1 alpha can induce the release of other cytokines, including IL-6 and IL-8, and is expressed throughout the epidermis when epidermal hyperplasia has been induced by repeated barrier disorders.
  • topical compositions which strengthen the barrier function of the skin, for example against transepidermal water loss, and at the same time reduce further negative skin reactions to environmental stress.
  • a further object of the present invention was to develop topical compositions which strengthen the barrier function of the skin and at the same time have a skin-calming and / or anti-inflammatory action.
  • a further object of the present invention was to develop topical compositions which strengthen the barrier function of the skin and at the same time have a calming and / or anti-inflammatory effect, without causing side effects such as may occur with corticosteroid-based anti-inflammatory agents.
  • a further object of the present invention was to develop cost-effective and production-optimized topical compositions which strengthen the barrier function of the skin.
  • taurine (2-aminoethanesulfonic acid)
  • taurine taurine on skin models significantly stimulates the synthesis of all three classes of barrier lipids, ceramides, cholesterols and fatty acids.
  • Taurine increases levels of ceramides, cholesterol and free fatty acids to the same extent. This property is of central importance because it is important to maintain the correct mixing ratio of the three barrier lipids (M.M. Man et al., Optimization of physiological lipid mixtures for barrier repair, J. Invest Dermatol., 106, 1096-101, 1996).
  • the condition of dry skin, sensitive skin and aging skin is sustainably improved.
  • Taurine is particularly suitable for the treatment of atopic dermatitis.
  • the use according to the invention of taurine for stimulating epidermal barrier lipid synthesis results in providing the barrier lipids via the secretory mechanism of the keratinocytes.
  • the barrier lipids are correctly enzymatically processed and functionally incorporated into the multilamellar lipid membranes.
  • the barrier function is permanently improved in this way. In particular, the effect is still present if the product is no longer used for a few days.
  • the use of taurine over the expensive synthetic ceramides offers economic advantages. Further economic and procedural advantages arise because taurine can be easily incorporated into the water phase, while (synthetic) barrier lipids can be processed only under (cost-increasing) energy input due to their high melting point.
  • taurine biochemically inhibits the release of inflammatory mediators induced by anionic surfactants and markedly improves the cellular vitality and integrity.
  • prostaglandin E2 was unexpected to the skilled person, since the chemical structure of taurine shows no similarity to known NSAIDs (non-steroidal anti-inflam- matory drugs).
  • taurine is present in an oil-in-water emulsion containing at least one linear primary fatty or wax alcohol having a chain length of the alkyl group of 20-40 carbon atoms. It is particularly preferred if the at least one linear primary fatty or wax alcohol having a chain length of the alkyl group of 20 to 40 carbon atoms is present in an amount such that at least one fumellated liquid crystal phase is present in the emulsion.
  • Such oil-in-water emulsions containing taurine and at least one linear primary fatty or wax alcohol having a chain length of the alkyl group of 20-40 carbon atoms, particularly preferably the at least one linear primary fatty or wax alcohol having a chain length of the alkyl group of 20 - 40 carbon atoms is contained in such an amount that at least one lamellar liquid crystal phase is present, solve the problems of the invention and strengthen the barrier function of the skin, especially against the transepidermal water loss. At the same time, they reduce further negative reactions of the skin to environmental stress, in particular they have a calming effect on the skin and / or anti-inflammatory, without causing side effects such as may occur with corticosteroid-based anti-inflammatory agents. In addition, they also have a pleasant, non-occlusive and non-sticky feel on the skin at the same time. They cause a long-lasting strengthening of the barrier function of the skin.
  • the present invention therefore relates to a cosmetic Haut adaptations ⁇ agent in the form of an oil-in-water emulsion containing taurine and at least one linear primary fatty or wax alcohol having a chain length of the alkyl group of 20 to 40 carbon atoms.
  • Another object of the present invention is the non-therapeutic use of a cosmetic skin treatment agent in the form of an oil-in-water emulsion containing taurine and at least one linear primary fatty or wax alcohol having a chain length of the alkyl group of 20-40 carbon atoms, for regeneration the skin barrier function.
  • Another object of the present invention is the non-therapeutic use of a cosmetic Skin treatment agent in the form of an oil-in-water emulsion containing taurine and at least one linear primary fatty or wax alcohol having a chain length of the alkyl group of 20-40 carbon atoms, for accelerating the regeneration of the skin barrier function.
  • Another object of the present invention is the Vietnamese ⁇ therapeutic use of a cosmetic skin treatment agent in the form of an oil-in-water emulsion containing taurine and at least one linear primary Fett ⁇ or wax alcohol having a chain length of the alkyl group of '20 - 40 carbon atoms Improving the appearance of dry skin.
  • Another object of the present invention is the non-therapeutic use of a cosmetic skin treatment agent in the form of an oil-in-water emulsion containing taurine and at least one linear primary fatty or wax alcohol having a chain length of the alkyl group of 20- 40 carbon atoms, for improvement the radiance of the skin.
  • a further subject of the present invention is the non-therapeutic use of a cosmetic skin treatment agent in the form of an oil-in-water emulsion containing taurine and at least one linear primary fatty or wax alcohol having a chain length of the alkyl group of 20-40 carbon atoms, for the care of dry and / or chapped lips.
  • a further subject of the present invention is the non-therapeutic use of a cosmetic skin treatment agent in the form of an oil-in-water emulsion containing taurine and at least one linear primary fatty or wax alcohol having a chain length of the alkyl group of 20-40 carbon atoms, for stimulating the epidermal synthesis of barrier lipids.
  • a further subject of the present invention is the non-therapeutic use of a cosmetic skin treatment agent in the form of an oil-in-water emulsion containing taurine and at least one linear primary fatty or wax alcohol having a chain length of the alkyl group of 20-40 carbon atoms, for the regeneration of the skin barrier function, for the acceleration of the regeneration of the skin barrier function or for the stimulation of the epidermal synthesis of barrier lipids and at the same time for skin calming and / or anti-inflammatory action.
  • Another object of the present invention is the use of a skin-treatment agent in the form of an oil-in-water emulsion containing taurine and at least one linear primary fatty or wax alcohol having a chain length of the alkyl group of 20- 40 carbon atoms, for the preparation of a therapeutic composition for Regeneration of the skin barrier function and, if appropriate, at the same time for skin calming and / or anti-inflammatory action.
  • a skin agent in the form of an oil-in-water emulsion containing taurine and at least one linear primary fatty or wax alcohol having a chain length of the alkyl group of 20-40 carbon atoms, for the preparation of a therapeutic Zu ⁇ composition for the treatment of atopic dermatitis.
  • compositions according to the invention are characterized in that they contain taurine in an amount of 0.001-5.0% by weight, preferably 0.05-3.0% by weight and more preferably 0.1-1.0% by weight. , in each case based on the weight of the total composition.
  • compositions according to the invention are characterized in that they contain at least one linear primary fatty or wax alcohol having a chain length of the alkyl group of 20-40 carbon atoms in a total amount of 0.5-15% by weight, preferably 0.8-10% by weight. %, more preferably 1-8 wt .-% and exceptionally preferably 1.5-5 wt .-%, each based on the weight of the total composition.
  • Preferred linear primary fatty or wax alcohols having a chain length of the alkyl group of 20 to 40 carbon atoms are selected from arachidyl alcohol (1-eicosanol), behenyl alcohol, lignoceryl alcohol (1-tetracosanol, C 24 H 50 O), ceryl alcohol (C 2B H 54 O), myricyl alcohol (1-triacontanol, C 30 H 62 O) and melissyl alcohol (C 31 H 64 O, 1-hentriacontanol). Particularly preferred are arachidyl alcohol and behenyl alcohol.
  • compositions according to the invention are therefore characterized in that the linear primary fatty or wax alcohol having a chain length of the alkyl group of 20-40 carbon atoms is selected from behenyl alcohol and arachidyl alcohol and mixtures of these substances.
  • arachidyl alcohol is present in amounts of 0.05-5% by weight, more preferably 0.1-4% by weight, based in each case on the weight of the total composition.
  • behenyl alcohol is present in amounts of from 0.5 to 4% by weight, more preferably from 1 to 2% by weight, based in each case on the weight of the total composition.
  • a mixture of arachidyl alcohol and behenyl alcohol is contained, wherein the preferred quantities mentioned for the individual substances are also considered to be preferred for the mixture.
  • the at least one linear primary fatty or wax alcohol having a chain length of the alkyl group of 20 to 40 carbon atoms in an amount such that at least one lamellar liquid phase is present in the emulsion.
  • Preferred compositions according to the invention are accordingly characterized in that the at least one linear primary fatty or wax alcohol having a chain length of the alkyl group of 20-40 carbon atoms is contained in such an amount that at least one lamellar liquid crystal phase is present in the oil-in-water emulsion ,
  • compositions according to the invention therefore additionally comprise at least one further cosmetic active ingredient which is selected from monomers, oligomers and polymers of amino acids, NC 2 -C 24 -acylamino acids and / or the esters and / or the physiologically compatible metal salts these substances, natural betaine compounds, vitamins, provitamins and vitamin precursors of groups A, B, C, E, H and K and the esters of the aforementioned substances, flavonoids and flavonoid-rich plant extracts, isoflavonoids and isoflavonoid-rich plant extracts, polyphenols and polyphenol -rich plant extracts, ubiquinone and ubiquinol and derivatives thereof, silymarin, ectoine, skin-soothing and moisturizing agents and mixtures of these active substances.
  • a further cosmetic active ingredient which is selected from monomers, oligomers and polymers of amino acids, NC 2 -C 24 -acylamino acids and / or the esters and / or the physiologically compatible metal salts these substances
  • the monomers of the amino acids and / or the NC 2 -C 24 -acylamino acids are selected from alanine, arginine, asparagine, aspartic acid, canavanine, citrulline, cysteine, Cystine, desmosine, glutamine, glutamic acid, glycine, histidine, homophenylalanine, hydroxylysine, hydroxyproline, isodesmosine, isoleucine, leucine, lysine, methionine, methylnoreleucine, ornithine, phenylalanine, proline, pyroglutamic acid, sarcosine, serine, threonine, thy ⁇ roxin, tryptophan, tyrosine, valine, zinc pyroglutamate, sodium octanoylglutamate, sodium decanoylglutamate, sodium lauroylglutamate, sodium myristoylglutamate, sodium cetoyl
  • the C 2 -C 24 -acyl radical with which said amino acids can be derivatized on the amino group is selected from an acetyl, propanoyl, butanoyl, pentanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl- , Decanoyl, undecanoyl, lauroyl, tridecanoyl, myristoyl, pentadecanoyl, cetoyl, palmitoyl, stearoyl, elaidoyl, arachidoyl or behenoyl radicals.
  • Mixtures of C 8 -C 18 acyl radicals are also referred to as cocoyl radical and are likewise preferred substituents.
  • the amino acids which carry an OH group can also be esterified at this OH group.
  • a preferred example of this according to the invention is hydroxyproline, which is N-acylated and esterified with two, preferably linear, C 2 -C 22 -fatty acid residues, more preferably dipalmitoylhydroxyproline, which is e.g. B. Sepilift DPHP available from the company Seppic.
  • the physiologically acceptable salts of the inventively preferred active ingredients containing acid groups and can form salts are selected from the ammonium, alkali metal, magnesium, calcium, aluminum, zinc and manganese salts. Preferred are the sodium, potassium, magnesium, aluminum, zinc and manganese salts.
  • amino acid oligomers are peptides having 2 to 30, preferably 2 to 15, amino acids.
  • the oligomers of the amino acids and / or the NC 2 -C 24 acylamino acids are preferably selected from di-, tri-, tetra-, penta-, hexa- or pentadecapeptides which may be N-acylated and / or esterified.
  • amino acid oligomers stimulate collagen synthesis or are able to recruit immune system cells, such as mast cells and macrophages, which then induce tissue repair processes via the release of growth factors, eg collagen synthesis, or are able to sequence them Arg-Phe-Lys in Thrombospondin I (TSP-1) to bind and thus active TGF-ß (tissue growth factor), which induces the synthesis of collagen in dermal fibroblasts set free.
  • TSP-1 Thrombospondin I
  • TGF-ß tissue growth factor
  • N-acylated and / or esterified dipeptides are acetyl-citrullyl-arginine (eg Exsy-algins of exsymol), Tyr-Arg (dipeptide-1), VaI-Trp (dipeptide-2), Asn Phe, Asp-Phe, N-palmitoyl-.beta.-Ala-His, N-acetyl-fyr-Arg-hexyldecylester (e.g., Sedorma calmosensins), camosin (.beta.-Ala-His) , and N-palmitoyl-Pro Arg.
  • acetyl-citrullyl-arginine eg Exsy-algins of exsymol
  • Tyr-Arg dipeptide-1
  • VaI-Trp dipeptide-2
  • Asn Phe Asp-Phe
  • N-acylated and / or esterified tripeptides are Gly-His-Lys, z. B. under the name "Omega-CH activator" by the company GfN or in acylated form (N-palmitoyl-Gly-His-Lys) under the name Biopeptide CL is available from Sederma, but (in acylated form) also a component of the product Matrixyl 3000 from Sederma
  • the tripeptide Gly-His-Lys can also be used as a copper salt (Cu 2+ ) and as such can be obtained from ProCyte Corporation, and analogues of Gly-His-Lys can be used
  • the substitution of Gly the following are suitable according to the invention: Ala, Leu and He
  • the inventively preferred amino acids which can replace His or Lys include a side chain with a nitrogen atom which is predominantly charged at pH 6, e.g.
  • Pro, Lys, Arg, His, desmosine and isodesmosine Lys is particularly preferably replaced by Arg, Om or citrulline
  • Another preferred tripeptide according to the invention is G ly-His-Arg (INCI name: Tripeptide-3) and its derivative N-myristoyl-Gly-His-Arg, the z.
  • N-acylated and / or esterified tetrapeptides are selected from Rigin and Rigin-based tetrapeptides and ALAMCAT tetrapeptides.
  • Rigin has the sequence Gly-Gln-Pro-Arg.
  • Rigin-based tetrapeptides include the Rigin analogs and Rigin derivatives, in particular the invention particularly preferred N-palmitoyl-Gly-Gln-Pro-Arg, z. B. is available under the name Eyeliss of Sederma, but also forms part of the product Matrixyl 3000 of Sederma.
  • the Rigin analogs include those in which the four amino acids are rearranged and / or in which a maximum of two amino acids are substituted to Rigin, z.
  • the sequence Ala-Gln-Thr-Arg.
  • at least one of the amino acids of the sequence has a Pro or Arg, and more preferably, the Tetrapeptide includes both Pro and Arg, and their order and position may vary.
  • the substituting amino acids can be selected from any amino acid defined below.
  • Particularly preferred rigin-based tetrapetides include: Xaa-Xbb-Arg-Xcc, Xaa-Xbb-Xcc-Pro, Xaa-Xbb-Pro-Arg, Xaa-Xbb-Pro-Xcc, Xaa-Xbb-Xcc-Arg, where Xaa , Xbb and Xcc may be the same or different amino acids and wherein Xaa is selected from Gly and the amino acids which may substitute Gly, Xbb is selected from GIn and the amino acids which can substitute for GIn, Xcc is selected from Pro or Arg and the Amino acids that can substitute Pro and Arg.
  • the preferred amino acids that can replace GIy include an aliphatic side chain, e.g. B. ⁇ -Ala, Ala, VaI, Leu, Pro, Sarcosine (Sar) and Isoleucine (He).
  • the preferred amino acids that can replace GIn include a side chain having an amino group that is predominantly uncharged at neutral pH (pH 6-7), eg, Asn, Lys, Om 1 5-hydroxyproline, citrulline, and canavanine.
  • the preferred amino acids which can replace Arg include a side chain having a nitrogen atom predominantly charged at pH 6, e.g. Pro, Lys, His, Desmosin and Isodesmosin.
  • Gly-Gln-Arg-Pro and Val-Val-Arg-Pro are preferred as Rigin analogues.
  • ALAMCAT tetrapeptides are tetrapeptides containing at least one amino acid with an aliphatic side chain, e.g. B. ⁇ -Ala, Ala, VaI, Leu, Pro, Sarcosine (Sar) and Isoleucine (Ue). Furthermore, ALAMCAT tetrapeptides include at least one amino acid having a side chain with an amino group predominantly uncharged at neutral pH (pH 6-7), e.g. GIn, Asn, Lys, Om, 5-Hydroxyproline, Citrulline and Canavanine. Furthermore, ALAMCAT tetrapeptides include at least one amino acid having a side chain with a nitrogen atom predominantly charged at pH 6, e.g.
  • ALAMCAT tetrapeptides may contain any amino acid; however, preferably the fourth amino acid is also selected from the three abovementioned groups.
  • N-acylated and / or esterified pentapep tides which are preferred according to the invention are selected from Lys-Thr-Thr-Lys-Ser and its N-acylated derivatives, more preferably N-palmitoyl-Lys-Thr-Thr-Lys-Ser , available under the name Matrixyl from the company Sederma, furthermore N-palmitoyl-Tyr-Gly-Gly-Phe-Met, VaI Val-Arg-Pro-Pro, N-palmitoyl-Tyr-Gly-Gly-Phe-Leu, Gly-Pro-Phe-Pro-Leu and N-benzyloxycarbonyl-Gly-Pro-Phe-Pro-Leu (the latter two Serine proteinase inhibitors for the inhibition of desquamation).
  • Preferred N-acylated and / or esterified hexapeptides according to the invention are VaI-Gly-ValiAla-Pro-Gly and its N-acylated derivatives, particularly preferably N-palmitoyl-Val-Gly-Val-Ala-Pro-Gly Acetyl-Hexapeptide-3 (Argireline from Lipotec), Hexapeptide-4 (eg CoIIa syn 6KS from Therapeutic Peptide Inc. (TPI)), Hexapeptide-, which is available under the name Biopeptide EL from Sederma.
  • VaI-Gly-ValiAla-Pro-Gly and its N-acylated derivatives particularly preferably N-palmitoyl-Val-Gly-Val-Ala-Pro-Gly Acetyl-Hexapeptide-3 (Argireline from Lipotec), Hexapeptide-4 (eg CoIIa syn 6KS from Therapeutic Peptide Inc. (TPI)), Hexapeptide-, which is
  • hexapeptide-8 e.g.
  • Collasyn 6KS from TPI myristoyl hexapeptide-8 (eg Collasyn Lipo-6KS from TPI), hexapeptide-9 (eg Collaxyl from Vincent) and hexapeptide-10 (eg Collaxyl from Vincience or Seriseline from Lipotec), Ala-Arg-His-Leu-Phe-Trp (hexapeptide-1), acetyl hexapeptide-1 (e.g., modulene from Vincience), acetyl glutamyl hexapeptide-1 (e.g., SNAP-7 from Centerchem), hexapep tide-2 (eg melanostatines-D M of Vincience), Ala-Asp-Leu-Lys-Pro-Thr (hexapeptide-3, e.g.
  • hexapeptide-4 e.g., Collasyn 6KS from Therapeutic Peptide Inc. (TPI)
  • hexapeptide-5 e.g., Collasyn 6VY from TPI
  • myristoyl hexapeptide-5 eg Collasyn 614VY from TPI
  • myristoyl hexapeptide-6 eg Collasyn 614VG from TPI
  • Ala-Arg-His-methylnorleucine homophenylalanine-Trp hexa-peptide- 7
  • hexapeptide-8 e.g., Collasyn 6KS from TPI
  • myristoyl hexapeptide-8 e.g., Collasyn Lipo-6KS from TPI
  • hexapeptide-9 e.g., Collaxyl from Vincience
  • Hexapeptides-10 eg, Collaminoes-10
  • Pentadeca- peptide is z.
  • Vinci 01 by Vincience Pentadecapeptide-1
  • Another preferred optional amino acid oligomer is the peptide derivative L-glutamylaminoethyl-indole (glistine from exsymol).
  • Another object of the present invention is the non-therapeutic use of a cosmetic skin treatment agent in the form of an oil-in-water emulsion containing taurine, at least one linear primary fatty or wax alcohol having a chain length of the alkyl group of 20- 40 carbon atoms and at least one cosmetic active ingredient selected from oligomers of amino acids, NC 2 -C 24 -acylamino acids and / or the esters and / or the Physio ⁇ logically acceptable metal salts of these substances, for the treatment of skin aging symptoms.
  • the polymers of the amino acids and / or the NC 2 -C 24 -acylamino acids are selected from plant and animal protein hydrolysates and / or proteins. Animal protein hydrolysates are z. B.
  • soy protein hydrolysates elastin, collagen, keratin, silk and milk protein protein hydrolysates, which may also be in the form of salts.
  • Vegetable protein hydrolysates eg. Soy, wheat, almonds, peas, potato and rice protein hydrolysates.
  • Corresponding commercial products are z. B. DiaMin® ® (Diamalt) Gluadin ® (Cognis), Lexein ® (Inolex) and Crotein ® (Croda).
  • soy protein hydrolysates e.g.
  • protein hydrolysates may also contain monomeric amino acids and oligopeptides; their composition is usually undefined.
  • acyl derivatives of protein hydrolysates z.
  • Corresponding commercial products are z.
  • Lamepon ® (Cognis), Gluadin ® (Cognis), Lexein ® (Inolex), Crolastin ® ® or Crotein (Croda).
  • cationic protein hydrolyzates whose underlying protein content has a molecular weight of from 100 to 25,000 daltons, preferably from 250 to 5,000 daltons.
  • cationic protein hydrolyzates are understood to mean quaternized amino acids and mixtures thereof.
  • the cationic protein hydrolyzates may be further derivatized.
  • cationic protein hydrolysates and derivatives used in the present invention some of the INCI names in the International Cosmetic Ingredient Dictionary and Handbook, (seventh edition 1997, The Cosmetic , Toiletry, and Fragrance Association 1101 17 th Street, NW, Suite 300, Washington, DC 20036-4702) and cited: Cocodimonium Hydroxypropyl Hydrolyzed Collagen, Steardimonium Hydroxypropyl Hydrolyzed Collagen, Cocodimonium Hydroxypropyl Hydrolyzed Rice Protein, Cocodimonium Hydroxypropyl Hydrolyzed SiC, Cocodimonium Hydroxypropyl Hydrolyzed Soy Protein, Cocodimonium Hydroxypropyl Hydrolyzed Wheat Protein, Cocodimonium Hydroxypropyl SiCl Amino Acids, Hydroxypropyl Arginine Lauryl / Myristyl Ether HCl Very particular preference is given to the cationic protein hydro
  • DNA repair enzymes preferred according to the invention are photolyase and , T4 endonuclease V, the latter abbreviated to "T4N5" below. These two enzymes are already known in the art as so-called DNA repair enzymes. DNA repair is defined as the cleavage or removal of UV-induced pyrimidine dimers from the DNA.
  • Photolyase is the abbreviation for deoxyribodipyrimidine photolyase or DNA photolyase, an enzyme with the classification number EC 4.1.99.3.
  • a particularly effi ⁇ tient photolyase comes from Anacystis nid ⁇ lans, a phototrophic marine microorganism.
  • the photolyase from A. nid ⁇ lans is now obtained in technically relevant quantities from E. coli.
  • Photolyase relies on light for activation.
  • the enzyme T4 endonuclease V is produced by the cfenV gene of bacteriophage T4 and belongs to the phosphodiesterases which hydrolytically cleave the nucleic acids at the (5 * -3 ') bond.
  • T4N5 is also active without the influence of light.
  • Liposome-encapsulated DNA repair enzymes are commercially available for. B. under the Pro ⁇ product name Photosomes TM, liposome-encapsulated T4N5 z. B. under the designation Ultrasomes TM by AGI Dermatics, USA, available.
  • the photo Some are TM or Ulfrasome TM in amounts of 0.1 - "10 wt .-%, preferably 0.5 - 5,0" wt .-%, and particularly preferably 1.0 - 4.0 Wt .-%, based on the total agent included.
  • the monomers, oligomers or polymers of amino acids, NC 2 -C 24 -acylamino acids and / or the esters and / or the physiologically tolerable metal salts of these substances are preferably present in amounts of 0.00001 - 10 wt .-%, particularly preferably from 0.001 to 5 wt .-% and most preferably 0.01 to 3 wt .-%, each based on the total composition.
  • the monomers, oligomers and polymers of amino acids, NC 2 -C 24 -acylamino acids, the esters and / or the physiologically tolerable metal salts of these substances are present in supported form, in particular applied to finely divided, pulverulent substrates such as silica gel, in particular Aerosil types, talc, microsponges, modified starches and starch derivatives, crystalline cellulose, cellulose pulp, lactoglobulin derivatives, polymer particles Nylon, polyolefins, polycarbonates, polyurethanes, polyacrylates, (meth) acrylate or (meth) acrylate-vinylidene copolymers, which may be crosslinked, polyesters, polyamides, polystyrenes, teflon and silicones
  • a particularly preferred raw material of this kind are the Vegetal Filling Spheres of Coletica.
  • compositions according to the invention additionally contain at least one DNA oligonucleotide or one RNA oligonucleotide.
  • an oligonucleotide is understood as meaning polymers of from 2 to 20, preferably from 2 to 10, mononucleotides which, like polynucleotides and nucleic acids, are linked by phosphoric diester bridges.
  • the nucleotides be ⁇ from nucleobases (usually pyrimidine or purine derivatives), pentoses (usually D-ribofuranose or 2-deoxy-D-ribofuranose in ß-N-glycosidic bond to the nucleobase) and phosphoric acid.
  • the mononucleotides are, for example, adenosine phosphates, cytidine phosphates, guanosine phosphates, uridine phosphates and thymidine phosphates, in particular CMP (cytidine 5'-monophosphate), UDP (uridine 5'-diphosphate), ATP (adenosine 5-triphosphate) and GTP (guanosine-5'-triphosphate).
  • CMP cytidine 5'-monophosphate
  • UDP uridine 5'-diphosphate
  • ATP adenosine 5-triphosphate
  • GTP guanosine-5'-triphosphate
  • An oligonucleotide particularly preferred according to the invention is the thymidine dinucleotide.
  • the DNA oligonucleotides or RNA oligonucleotides are preferably present in amounts of 0.00001-5 wt%, more preferably 0.0001-1.0 wt%, and most preferably 0.0005 - 0.5 wt .-%, based on the total agent included.
  • compositions according to the invention additionally comprise at least one natural betaine compound.
  • Natural betaine compounds used in accordance with the invention are naturally occurring compounds with the atomic grouping R 3 N + -CH 2 -X-COO " according to IUPAC rule C-816.1 So-called betaine surfactants (synthetic) do not fall under the betaine compounds used according to the invention, nor any other zwitterionic Compounds in which the positive charge on N or P and the negative charge are formally O, S, B or C but which do not conform to IUPAC Rule C-816.1
  • the betaine compounds are preferably in the compositions of the invention in a total amount of 0.05 to 5 wt .-%, particularly preferably 0.1 to 3 Wt .-%, most preferably 0.5 to 2 wt .-%, each based on the total composition.
  • compositions according to the invention additionally comprise at least one vitamin, provitamin or a compound designated as vitamin precursor from the vitamin groups A, B, C, E, H and K or the esters of the abovementioned substances.
  • vitamin A includes retinol (vitamin A 1 ) and 3,4-didehydroretinol (vitamin A 2 ).
  • the ß-carotene is the provitamin of retinol.
  • vitamin A component according to the invention for example, vitamin A acid and its esters, vitamin A aldehyde and vitamin A alcohol and its esters, such as retinyl palmitate and retinyl acetate into consideration.
  • the preparations according to the invention preferably contain the vitamin A component in amounts of 0.05-1% by weight, based on the total composition.
  • the vitamin B group or the vitamin B complex include, among others
  • Vitamin B 1, thiamine trivial name, chemical name 3 - [(4 '-amino-2' - methyl-5 '-pyrimidinyl) methyl] -5- (2-hydroxyethyl) -4-methylthiazolium chloride.
  • Thiamine hydrochloride is preferably used in amounts of from 0.05 to 1% by weight, based on the total agent.
  • Vitamin B 2 trivial name riboflavin, chemical name 7-, 8-dimethyl-10- (1-d-ribityl) -benzo [g] pteridine-2,4 (3H, 10 / - /) - dione.
  • Riboflavin or its derivatives are preferably used in amounts of from 0.05 to 1% by weight, based on the total agent.
  • the compounds nicotinic acid and nicotinamide are performed.
  • Preferred according to the invention is the nicotinic acid amide, which is preferably present in the agents according to the invention in amounts of from 0.05 to 1% by weight, based on the total agent.
  • pantothenic acid and panthenol Panthenol is preferably used.
  • Derivatives of panthenol which can be used according to the invention are, in particular, the esters and ethers of panthenol and also cationically derivatized panthenols.
  • derivatives of 2-furanone instead of and in addition to pantothenic acid or panthenol, it is also possible to use derivatives of 2-furanone having the general structural formula (I).
  • the substituents R 1 to R 6 independently of one another are a hydrogen atom, a hydroxyl radical, a methyl, methoxy, aminomethyl or hydroxymethyl radical, a saturated or mono- or diunsaturated, linear or branched C 2 -C 4 - hydrocarbon radical, a saturated or mono- or diunsaturated, branched or linear mono-, di- or trihydroxy-C 2 -C 4 - hydrocarbon radical or a saturated or mono- or diunsaturated, branched or linear Mono, di or TrJa (TiJnO-C 2 -C 4 - hydrocarbon radical.)
  • Particularly preferred derivatives are the commercially available substances dihydro-3-hydroxy-4,4-dimethyl-2 (3H) -furanone with the trivial name Pantolactone (Merck), 4-hydroxymethyl- ⁇ -butyrolactone (Merck), 3,3-dimethyl-2-hydroxy- ⁇ -butyrolactone (Aldrich
  • the extremely preferred 2-furanone derivative according to the invention is pantolactone (dihydro-3-hydroxy-4,4-dimethyl-2 (3H) -furanone), where in formula (I) R 1 is a hydroxyl group, R 2 is a hydrogen atom, R 3 and R 4 represent a methyl group and R 5 and R 6 represent a hydrogen atom.
  • the stereoisomer (R) - pantolactone is formed during the degradation of pantothenic acid.
  • the said compounds of the vitamin B 5 type and the 2-furanone derivatives are in preferred agents according to the invention in a total amount of 0.05 to 5 wt .-%, particularly preferably 0.1 to 3 wt .-%, most preferably 0.5 to 2 wt .-%, each based on the total composition included.
  • Vitamin B 6 which is understood hereunder not a uniform substance, but the known under the common names pyridoxine, pyridoxamine and pyridoxal derivatives of 5-hydroxymethyl-2-methylpyridin-3-ol.
  • Vitamin B 6 is preferably present in the inventive compositions in amounts of from 0.0001 to 1.0% by weight, in particular in amounts of from 0.001 to 0.01% by weight.
  • - Vitamin B 7 also known as vitamin H or "skin vitamin”. Biotin is (3aS, 4S, 6aR) -2-oxohexahydrothienol [3,4-c /] imidazole-4-valeric acid.
  • Biotin is preferably present in the compositions according to the invention in amounts of from 0.0001 to 1.0% by weight, in particular in amounts of from 0.001 to 0.01% by weight.
  • Vitamin C is preferably used in amounts of from 0.1 to 3% by weight, based on the total composition.
  • the use of the derivatives ascorbyl palmitate, stearate, dipalmitate, acetate, Mg ascorbyl phosphate, Na ascorbyl phosphate, sodium and magnesium ascorbate, disodium ascorbyl phosphate and sulfate, potassium ascorbyl tocopheryl phosphate, chitosan ascorbate or ascorbyl glucoside may be preferred.
  • the use in combination with tocopherols may also be preferred.
  • the vitamin E group includes tocopherol, especially ⁇ -tocopherol, and its derivatives.
  • esters such as tocopheryl acetate, nicotinate, phosphate, succinate, linoleate, oleate, tocophereth-5, tocophereth-10, tocophereth-12, tocophereth-18, tocophereth-50 and tocopherol.
  • Tocopherol and its derivatives are preferably present in amounts of from 0.05 to 1% by weight, based on the total composition.
  • Vitamin F is usually understood as meaning essential fatty acids, in particular linoleic acid, linolenic acid and arachidonic acid.
  • Vitamin H is another name for biotin or vitamin B 7 (see above).
  • the fat-soluble vitamins of the vitamin K group which are based on the basic structure of 2-methyl-1,4-naphthoquinone, include phylloquinone (vitamin K 1 ), farno- quinone or menaquinone-7 (vitamin K2) and menadione (vitamin K 3 ).
  • Vitamin K is preferably present in amounts of 0.0001 to 1.0% by weight, in particular 0.01 to 0.5% by weight, in each case based on the total composition.
  • Vitamin A palmitate (retinyl palmitate), panthenol, pantolactone, nicotinamide, pyridoxine, pyridoxamine, pyridoxal, biotin, ascorbyl palmitate, ascorbyl acetate, magnesium ascorbyl phosphate, sodium ascorbyl phosphate, sodium and magnesium ascorbate and the tocopherol esters, especially tocopheryl acetate, are particularly preferred according to the invention prefers.
  • compositions according to the invention additionally contain at least one flavonoid or a flavonoid-rich plant extract.
  • the flavonoids preferred according to the invention include the glycosides of the flavones, the flavanones, the 3-hydroxyflavones (flavonols), the aurones and the Isoflavones. Particularly preferred flavonoids are selected from naringin (aurantiine,
  • Naringenin-7-rhamnoglucoside ⁇ -glucosylrutin, ⁇ -glucosylmyricetin, ⁇ -glucosylisoquercetin, ⁇ -glucosylquercetin, hesperidin (3 ', 5,7-trihydroxy-4'-methoxyflavanone-
  • Extremely preferred flavonoids according to the invention are ⁇ -glucosylrutin, naringin and apigenin-7-glucoside.
  • flavonoids are constructed from two flavonoid biflavonoids, z. B. occur in gingko species.
  • Other preferred flavonoids are the chalcones, especially phloricin and neohesperidin dihydrochalcone.
  • the flavonoids are preferably used in amounts of from 0.0001 to 1% by weight.
  • Composition used.
  • compositions according to the invention additionally contain at least one isoflavonoid or an isoflavonoid-rich plant extract.
  • the isoflavones and the isoflavone glycosides are counted at this point as isoflavonoids.
  • isoflavones are to be understood as meaning substances which are hydrogenation, oxidation or substitution products of 3-phenyl-4H-1-benzopyran, hydrogenation of which may be in the 2,3-position of the carbon skeleton, oxidation under Formation of a carbonyl group in the 4-position may be present, and by substitution of the replacement of one or more hydrogen atoms by hydroxy or methoxy groups to understand.
  • the isoflavones preferred according to the invention include, for example, daidzein, genistein, prunetin, biochanin, orobol, santal, pratense, irigenin, glycitein, biochanin A and formononetin.
  • Particularly preferred isoflavones are daidzein, genistein, glycitein and formononetin.
  • the isoflavones are glycosidically linked via at least one hydroxyl group to at least one Zücker.
  • Sugars are mono- or oligosaccharides, in particular D-glucose, D-galactose, D-glucuronic acid, D-galacturonic, D-xylose, D-apiose, L-rhamnose, L-arabinose and rutinose into consideration.
  • Particularly preferred isoflavone glycosides according to the invention are daidzin and genistin.
  • the isoflavones and / or their glycosides are contained in the preparations as constituents of a substance mixture obtained from a plant, in particular a plant extract.
  • a substance mixture obtained from a plant in particular a plant extract.
  • Such vegetable substance mixtures can be obtained in a manner familiar to the person skilled in the art, for example by squeezing or extracting from plants such as soy, in particular from soybean, red clover or chickpeas.
  • Isoflavones or isoflavone glycosides in the form of extracts obtained from soybean are particularly preferably used in the preparations according to the invention, as described, for example, under the product name Soy Protein Isolate SPI (Protein Technology International, St.
  • isoflavonoid-rich plant extract is apple seed extract, in particular the commercial product Ederline from Seporga.
  • Ederline contains phytohormones, isoflavonoids, phytosterols, triterpenoids, tocopherols and natural waxes.
  • the isoflavonoids are preferably used in amounts of from 0.00001 to 1% by weight, more preferably from 0.0005 to 0.5% by weight and most preferably from 0.001 to 0.1% by weight, based in each case on the isoflavonoid active substance the entire composition used.
  • compositions according to the invention additionally comprise at least one polyphenol or a polyphenol-rich plant extract.
  • polyphenols are aromatic compounds which contain at least two phenolic hydroxyl groups in the molecule. These include the three dihydroxybenzenes catechol, resorcinol and hydroquinone, phloroglucin, pyrogallol and hexahydroxybenzene.
  • free and etherified polyphenols occur, for example, in floral dyes (anthocyanidins, flavones), in tannins (catechins, tannins), as lichen or fern ingredients (usnic acid, acylpolyphenols), in lignins and as gallic acid derivatives.
  • Preferred polyphenols are flavones, catechins, usnic acid, and as tannins the derivatives of gallic acid, digallic acid and digalloylgallic acid.
  • Particularly preferred polyphenols are the monomeric catechins, that is, the derivatives of flavan-3-ols, and leucoanthocyanidins, that is to say the derivatives of leucoanthocyanidins which preferably carry phenolic hydroxyl groups in the ⁇ J, -S '''S' position, preferably epicatechin and epigallocatechin, and also the tanning agents resulting therefrom by self-condensation.
  • Such tannins are preferably not used in isolated pure substance, but as extracts of tanning-rich plant parts, eg. B. Extracts of catechu, quebracho, oak bark and pine bark and other Baumrin ⁇ the leaves of green tea (camellia sinensis) and mate. Also particularly preferred are the tannins.
  • a particularly preferred polyphenol-rich cosmetic active ingredient is the commercial product Sepivinol R 1, an extract of red wine, available from Seppic.
  • Another particularly preferred polyphenol rich cosmetic active ingredient is the commercial product Crodarom Chardonnay, an extract from the cores of the Chardonnay grape, available from Croda.
  • the polyphenols are preferably used in amounts of from 0.001 to 10% by weight, more preferably from 0.005 to 5% by weight and most preferably from 0.01 to 3% by weight, based in each case on the total composition.
  • compositions additionally at least one ubiquinone or ubiquinol or their
  • Ubiquinols are the reduced form of ubiquinone.
  • Ubiquinones have the formula (II):
  • ubiquinone of formula (II) with n 6, 7, 8, 9 or 10.
  • the ubiquinones, ubiquinols or their derivatives are preferably used in amounts of 0.0001 to 1 wt .-%, particularly preferably 0.001 to 0.5 wt .-% and most preferably 0.005 to 0.1 wt .-%, each based on the entire composition used.
  • compositions according to the invention additionally contain silymarin.
  • silymarin is an active substance concentrate from the fruits of the milk thistle (Silybum marianum) which was previously regarded as a uniform substance.
  • the main constituents of the silymarine are silybin (silymarin I), silychristin (silymarin II) and silydianin, which belong to the group of flavanolignans.
  • Silymarin is particularly preferably used in liposome-encapsulated form, available for. Under the trade name Silymarin Phytosome (INCI: Silybum Marianum Extract and Phospholipids) from lndena SpA.
  • silymarin is preferably used in amounts of from 0.0001 to 1% by weight, more preferably from 0.001 to 0.5% by weight, and most preferably from 0.005 to 0.1% by weight, based in each case on the active substance in the entire composition, used.
  • compositions according to the invention additionally comprise ectoine.
  • Ectoin is the common name for 2-methyl-1, 4,5,6-tetrahydropyrimidine-4-carboxylate.
  • ectoine is preferably present in amounts of from 0.0001 to 1% by weight, more preferably from 0.001 to 0.5% by weight, and most preferably from 0.005 to 0.01% by weight, based in each case on the total composition.
  • compositions according to the invention additionally comprise at least one skin-soothing or moisturizing active ingredient.
  • Skin-soothing active ingredients preferred according to the invention are selected from allantoin, ⁇ -bisabolol, ⁇ -lipoic acid, extracts from Centella asiatica, for example obtainable under the name Madecassicoside from DSM, glycyrrethic acid, which is particularly preferably encapsulated in liposomes and in this form z.
  • Allantoin ⁇ -bisabolol
  • ⁇ -lipoic acid extracts from Centella asiatica, for example obtainable under the name Madecassicoside from DSM
  • glycyrrethic acid which is particularly preferably encapsulated in liposomes and in this form z.
  • the skin-soothing active ingredients other than taurine are preferred in amounts of 0.001 to 5 wt .-%, particularly preferably 0.01 to 2 wt .-% and extraordinarily preferably 0.1 to 1 wt .-%, respectively based on the total composition.
  • preferred moisturizing agents are selected from Desoxyzuckem, particularly preferably rhamnose and fucose, polysaccharides min ⁇ least one deoxysugar block included, particularly preferably Christmaspro ⁇ domestic product Fucogel ®, urea, (2-hydroxyethyl) urea, glycosaminoglycans, particularly preferably hyaluronic acid , Dextran, dextran sulfate, chondroitin 4-sulfate and chondroitin 6-sulfate.
  • the moisturizing active ingredients are preferably present in amounts of 0.001 to 5% by weight, more preferably 0.01 to 2% by weight and most preferably 0.1 to 1% by weight, based in each case on the total composition.
  • Epidermis models were topically incubated for 1 hour with an aqueous solution of 0.18% SDS in water. As expected, this treatment resulted in a significant reduction in cellular vitality, an increased release of LDH (lac- dehydrogenase), interleukin 1-alpha (IL-1 alpha) and prostaglandin E2 (PGE2).
  • LDH lac- dehydrogenase
  • IL-1 alpha interleukin 1-alpha
  • PGE2 prostaglandin E2
  • C corticosteroid ratiopharm® cream (0.1% by weight triamcinolone acetonide);
  • D 1, 5 wt .-% behenyl alcohol + 2.75 wt .-% arachidyl alcohol;
  • E 1, 5 wt .-% behenyl alcohol + 2.75 wt .-% arachidyl alcohol +1 wt .-% taurine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)

Abstract

L'invention se rapporte à un agent de traitement cosmétique pour la peau se présentant sous la forme d'une émulsion huile dans eau, contenant de la taurine et au moins un alcool de cire ou un alcool gras linéaire primaire dont le groupe alkyle présente une longueur de chaîne comportant entre 20 et 40 atomes de carbone. Cette invention concerne également l'utilisation non thérapeutique d'un agent de traitement cosmétique pour la peau se présentant sous la forme d'une émulsion huile dans eau, contenant de la taurine et au moins un alcool de cire ou un alcool gras linéaire primaire dont le groupe alkyle présente une longueur de chaîne comportant entre 20 et 40 atomes de carbone, pour régénérer la fonction barrière de la peau.
EP05770481A 2004-08-13 2005-08-05 Compositions cosmetiques pour traiter une peau stressee contenant de la taurine et des alcools gras a chaine longue Withdrawn EP1776084A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE200410039550 DE102004039550A1 (de) 2004-08-13 2004-08-13 Kosmetische und dermatologische Zusammensetzungen mit (2-Hydroxyethyl)harnstoff
DE102005022626A DE102005022626A1 (de) 2005-05-11 2005-05-11 Kosmetische Zusammensetzungen zur Behandlung gestresster Haut
PCT/EP2005/008480 WO2006018149A1 (fr) 2004-08-13 2005-08-05 Compositions cosmetiques pour traiter une peau stressee contenant de la taurine et des alcools gras a chaine longue

Publications (1)

Publication Number Publication Date
EP1776084A1 true EP1776084A1 (fr) 2007-04-25

Family

ID=35064541

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05770481A Withdrawn EP1776084A1 (fr) 2004-08-13 2005-08-05 Compositions cosmetiques pour traiter une peau stressee contenant de la taurine et des alcools gras a chaine longue

Country Status (2)

Country Link
EP (1) EP1776084A1 (fr)
WO (1) WO2006018149A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005022625A1 (de) * 2005-05-11 2006-11-23 Henkel Kgaa Verwendung von Taurin zur Steigerung der epidermalen Lipidsynthese
US8821839B2 (en) 2010-10-22 2014-09-02 Conopco, Inc. Compositions and methods for imparting a sunless tan with a vicinal diamine
ES2652521T3 (es) 2011-09-26 2018-02-02 Unilever N.V. Composición para el cabello
US8961942B2 (en) 2011-12-13 2015-02-24 Conopco, Inc. Sunless tanning compositions with adjuvants comprising sulfur comprising moieties
DE102011089270A1 (de) * 2011-12-20 2013-06-20 Henkel Ag & Co. Kgaa Verwendung von einer Kombination von Taurin und hydrolysiertem Protein aus Hefe zur Steigerung der epidermalen Lipidsynthese
EP2897605A1 (fr) * 2012-09-21 2015-07-29 Nestec S.A. Composition comprenant des phénols végétaux pour la prévention ou la réduction de la perte d'eau transépidermique et de troubles et maladies associés
CA2974196C (fr) * 2015-01-20 2023-12-12 TetraDerm Group LLC Vehicule d'administration de medicament topique polyvalent et hydratant tissulaire multifactoriel qui permet la restauration de la barriere muqueuse et cutanee
CN112353789B (zh) * 2015-12-25 2022-05-17 北京乳凝创智生物技术研发中心（有限合伙） 一种化妆品
WO2021173160A1 (fr) * 2020-02-28 2021-09-02 Chanda Zaveri Préparations pour la pousse des cheveux et le cuir chevelu

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753648B2 (ja) * 1986-07-07 1995-06-07 株式会社コーセー 水中油型乳化化粧料
JPH05310549A (ja) * 1992-05-13 1993-11-22 Taisho Pharmaceut Co Ltd 皮膚外用剤
DE19713793A1 (de) * 1997-04-03 1998-10-08 Henkel Kgaa Öl-in-Wasser-Emulsionen zur Wiederherstellung der Lamellarität der Lipidstruktur geschädigter Haut
DE10133202A1 (de) * 2001-07-07 2003-01-16 Beiersdorf Ag Osmolyte enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
DE10355229A1 (de) * 2003-11-26 2005-06-23 Beiersdorf Ag Kosmetikartikel mit verbesserter Penetration eines Wirkstoffs durch gleichzeitig anzuwendende abrasive Vorrichtung
DE102004014615A1 (de) * 2004-03-23 2005-10-13 Beiersdorf Ag Taurinhaltige Zubereitungen zur Verbesserung der Hautbarriere

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006018149A1 *

Also Published As

Publication number Publication date
WO2006018149A1 (fr) 2006-02-23

Similar Documents

Publication Publication Date Title
EP1803435B1 (fr) Compositions cosmétiques dotées d'une protection contre les rayonnements solaires sur la base d'émulsions lamellaires
DE102006046076A1 (de) Kosmetische und dermatologische Zusammensetzungen mit Oligopeptiden und Apfelextrakt
EP1776084A1 (fr) Compositions cosmetiques pour traiter une peau stressee contenant de la taurine et des alcools gras a chaine longue
EP1634576A1 (fr) Préparations cosmétiques ou dermatologiques contenant des enzymes de réparation de l' ADN et des oligopeptides
WO2006018198A1 (fr) Compositions cosmetiques et dermatologiques a base de (2-hydroxyethyl)uree
EP1812121A1 (fr) Compositions cosmetiques et dermatologiques pour le traitement des peaux matures
DE102005063062A1 (de) Synergistische Proteinhydrolysat-Kombinationen zur Behandlung reifer Haut
EP1949887A2 (fr) Compositions cosmétiques destinées au lissage et à l'affinement de la peau
EP1938789A1 (fr) Amélioration de la tolérance de la peau aux agents actifs hyperémiants
EP2005941A2 (fr) Compositions rajeunissant les cellules
WO2013091975A1 (fr) Compositions biomimétiques pour le nettoyage et les soins de la peau
EP2266529A2 (fr) Cosmétique de protection UV
WO2010049389A1 (fr) Compositions cosmétiques et dermatologiques pour la réduction tridimensionnelle des rides
EP2011476A2 (fr) Compositions cosmétiques et dermatologiques hydratantes avec promoteurs
EP2263643A2 (fr) Cosmétique antiride comprenant des extrait de plants
DE102007022448A1 (de) Mittel zur Hautaufhellung
DE102009037537A1 (de) Antifalten-Kosmetikum
DE102006062566A1 (de) Kosmetische und dermatologische Zusammensetzungen gegen unreine Haut und/oder Akne
EP1799311A2 (fr) Compositions comprenant des inhibiteurs de la synthese de la prostaglandine et/ou du leucotriene en combinaison avec des stimulateurs de liberation de neuromediateurs cutanes
DE102010063585A1 (de) W/O-Emulsionen
DE102010026465A1 (de) Kosmetikum zur Verbesserung der Struktur gealterter Haut
EP2633887B1 (fr) Combinaison de principes actifs d'un nouveau type pour une action anti-plis efficace
EP2238964A2 (fr) Compositions cosmétiques stabilisées
DE102009002227A1 (de) Hautbehandlungsmittel gegen Hautalterung I
DE102005026357A1 (de) Kosmetische und dermatologische Zusammensetzungen zur Behandlung reifer oder lichtgeschädigter Haut

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HENKEL AG & CO. KGAA

17Q First examination report despatched

Effective date: 20081029

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100302